Skip to search formSkip to main contentSkip to account menu

maytansinol

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2012
2012
During impurity analysis of maytansinol (2), produced from the reduction of ansamitocin P‐3 (AP‐3, 1), a surprisingly stable… 
2012
2012
The present invention, compounds of general formula 1, relates SIRT-1 activator derivatives thereof or pharmaceutically… 
2011
2011
La presente invention a pour objet des intermediaires linker-medicament de Formule I qui sont conjugues a des anticorps pour… 
2011
2011
A compound selected from Formula I: ** ** Formula wherein: L is: ** ** Formula E Formula ** ** is n is 2, 3, 4, 5 or 6; m is 2, 3… 
2006
2006
A process for preparing maytansinol comprising: a) reducing a C3-ester of maytansinol with a reducing hydride reagent with… 
2006
2006
The present invention, the processing steps were minimized, to reduce the dose of the solvent, by a method for a more efficient… 
2003
2003
Methods of preparing maytansinol from disulfide-containing maytansinoid esters by reduction with LiAlH The maytansinol is useful… 
1986
1986
Maytansinol (1) is the common precursor of maytansinoids (2), which are the 3-0-acyl derivatives of 1 and generally show… 
1984
1984
Several semisynthetic maytansinoids that differ in the structure of the acyl group at the C3 position were prepared by acylation… 
1981
1981
Bacteria, actinomycetes, yeasts, and fungi were screened for their ability to modify the structure of ansamitocins, a group of…